Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Inclusion Criteria: * Male or female, 18 to 75 years of age * Written informed consent * Body mass index (BMI) between 17.5 and 30.0 kg/m2 * No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment * No abnormal finding of clinical relevance * Diagnosis of HBeAg positive, immune active, chronic HBV infection * \> 2 months of continuous treatment with daily oral entecavir or tenofovir * Must use 2 effective methods of contraception (double barrier contraception or hormonal contraceptive along with a barrier contraceptive) Exclusion Criteria: * Pregnant or lactating * Acute signs of hepatitis/other infection within 4 weeks of screening * Hepatic transaminases (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]) \> 3 times the upper limits of normal * Liver Elastography (i.e. FibroScan®) score \> 9 * Antiviral therapy other than entecavir or tenofovir within 3 months of screening * Prior treatment with interferon in the last 3 years * Use of anticoagulants, corticosteroids, immunomodulators, or immunosuppressants within 6 months of screening * Use within 7 days prior to screening of dietary and/or herbal supplements that can interfere with liver metabolism * Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days of study drug administration * Use of prescription medication within 14 days prior to study drug administration * Depot injection/implant of any drug except birth control within 3 months prior…